From Nasdaq: 2025-04-27 23:42:00

Pfizer is set to report earnings on April 29, 2025. In the last five years, the stock has shown a 50-50 split between positive and negative returns following earnings announcements, with a median one-day return of 2.7% when positive. Analysts expect earnings of $0.68 per share on sales of $14.11 billion.

Vyndaqel is expected to be the key growth driver for Pfizer, likely leading to double-digit sales growth excluding Covid-19 products. Historical performance data can guide event-driven traders in approaching post-earnings stock movement, with two potential strategies based on past patterns.

For those seeking lower volatility, the Trefis High Quality portfolio offers an alternative to individual stocks, outperforming the S&P 500 and generating over 91% returns since inception. Historical odds show a 50% chance of positive one-day post-earnings returns for Pfizer, with a median positive return of 2.7% and negative return of -1.3%.



Read more at Nasdaq: How Will Pfizer Stock React To Its Upcoming Earnings?